Acute lymphocytic leukaemia refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acute lymphocytic leukaemia refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression https://clinicaltrials.eu/trial/a-study-testing-azd3632-alone-or-with-other-anticancer-drugs-in-adults-with-acute-leukemia-or-myelodysplastic-syndromes-with-hox-gene-overexpression/ Wed, 29 Apr 2026 15:08:03 +0000 https://clinicaltrials.eu/trial/a-study-testing-azd3632-alone-or-with-other-anticancer-drugs-in-adults-with-acute-leukemia-or-myelodysplastic-syndromes-with-hox-gene-overexpression/ This study involves adults with certain types of blood cancers that have come back or did not respond to previous treatments. The blood cancers being studied include acute leukemia and myelodysplastic syndromes, which are conditions where the bone marrow does not produce healthy blood cells properly. These particular cancers have specific genetic changes that cause overactivity of certain genes called HOX genes. The genetic changes include mutations such as NPM1 mutation, KMT2Ar rearrangements, and several other genetic alterations. The treatment being tested is a medication called AZD3632, which is given as a tablet by mouth. In one part of the study, AZD3632 is given alone, and in another part, it is given together with posaconazole, which is another medication.

The purpose of this study is to learn how safe AZD3632 is, how well the body tolerates it, how it moves through the body over time, and whether it might help treat these blood cancers. The study is divided into different modules or parts. The first module tests AZD3632 by itself to find the best dose that is both safe and effective. This module also includes a smaller part that looks at whether eating food affects how the body absorbs the medication. The second module tests AZD3632 when given together with posaconazole to see if this combination is safe and to understand how the two medications interact in the body.

During the study, participants will take the study medication and visit the clinic regularly for check-ups. These visits will include physical examinations, blood tests to check how the body is functioning, heart monitoring tests, and assessments to see how the disease is responding to treatment. The doctors will monitor for any side effects and measure various aspects of how the medication works in the body, including the levels of medication in the blood at different times. For participants with acute leukemia, the doctors will look for signs that the cancer is responding, such as a reduction in cancer cells in the bone marrow and blood. For those with myelodysplastic syndromes, the doctors will check whether blood cell counts improve and whether participants need fewer blood transfusions. The study will also track how long any positive responses last and overall survival.

]]>